Krystal Biotech (KRYS) Total Non-Current Liabilities (2018 - 2026)

Krystal Biotech has reported Total Non-Current Liabilities for 5 years, with the latest figure at $134.4 million in Q2 2026.

• Total Non-Current Liabilities for Q2 2026 came in at $134.4 million, up 41.6% year-over-year; the trailing twelve-month figure through Jun 2026 was $134.4 million (up 41.6% YoY), and the FY2025 annual result was $110.5 million, up 2.29% from the prior year.
• Total Non-Current Liabilities climbed to $134.4 million in Q2 2026, from $115.1 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $134.4 million in Q2 2026 and troughed at $39.7 million in Q4 2023.
• A 4-year average of $96.3 million and a median of $97.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The widest annual swing landed in 2024, when Total Non-Current Liabilities jumped 172.04%; it then advanced 2.29% in 2025.
• A 4-year view of Total Non-Current Liabilities shows it stood at $39.7 million in 2023, then jumped by 172.04% to $108.0 million in 2024, then advanced by 2.29% to $110.5 million in 2025, then advanced by 21.66% to $134.4 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $134.4 million in Q2 2026, $115.1 million in Q1 2026, and $110.5 million in Q4 2025.